Full-Time

Patient Billing Associate

Posted on 1/22/2025

BillionToOne

BillionToOne

201-500 employees

Molecular diagnostics for prenatal and oncology testing

Biotechnology
Healthcare

Compensation Overview

$51kAnnually

+ Quarterly Bonus

Junior, Mid

Remote in USA

Category
Customer Support
Customer Success & Support
Required Skills
Salesforce
Customer Service

You match the following BillionToOne's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 2+ years of prior client-facing experience
  • Inside Sales / Customer Service background in a fast paced, high-volume environment strongly preferred
  • Experience using Salesforce
  • Advanced organizational skills with the ability to handle multiple assignments.
  • Fast learner with the ability to navigate complex workflows and technology
  • Outstanding verbal, written and presentation skills - ability to effectively tailor messages to different audiences.
Responsibilities
  • Personally engage customers in a positive and friendly manner to proactively resolve issues that may impact account growth or retention
  • Oversee and effectively respond to all types of communication in a courteous and articulate manner: phone, email, and web inquiries from customers (physician offices), field sales representatives, and existing or potential patients.
  • Handle a variety of inquiries, including questions about our technology, products, and services, costs, billing, and insurance coverage.
  • Keep precise and clear documentation of all communications and follow-up activities.
  • Contact patients through outbound calling and SMS to explain potential costs and address billing concerns
  • Contact physicians and other medical personnel to obtain missing information that is pertinent to reimbursement
  • Manage a queue of customers that need to be contacted and effectively follow through on a scheduled contact cadence until resolved
  • Handle 20-30 inbound calls and 40-50 outbound calls per day
Desired Qualifications
  • Speaking fluently in Spanish

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases by identifying minute variations in DNA at a single base-pair level. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to enhance the precision and efficiency of molecular testing, ultimately making a positive impact on healthcare.

Company Size

201-500

Company Stage

Series D

Total Funding

$380.2M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne achieved over 100% revenue growth, reaching $153 million in 2024.
  • The company secured a billion-dollar valuation with a $130 million funding round.
  • Expansion in Austin, Texas, will create 1,000 jobs and increase production capacity.

What critics are saying

  • Emerging startups in molecular diagnostics could erode BillionToOne's market share.
  • Rapid technological advancements require continuous innovation to maintain competitiveness.
  • Economic instability in target markets may affect product affordability and adoption.

What makes BillionToOne unique

  • BillionToOne's QCT technology detects DNA variations at single base-pair resolution.
  • Their non-invasive prenatal tests replace risky procedures like amniocentesis.
  • Northstar products offer precise therapy selection and monitoring for oncology patients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

3%
PR Newswire
Jan 28th, 2025
Billiontoone Reports Over 100% Growth In Revenue Year-Over-Year

Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne

Webrazzi
Dec 30th, 2024
2024 Yılında En Çok Yatırım Alan 10 Yerli Girişim

2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu

PR Newswire
Dec 23rd, 2024
Billiontoone To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Dec. 23, 2024 /PRNewswire/ -- BillionToOne, a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that they will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2025.BillionToOne marks a transformative year of achievements as it looks toward 2025. The company closed an oversubscribed, upsized Series D funding round led by Premji Invest in June, and was recently recognized as the Biotech Breakthrough Awards' Diagnostics Company of the Year. More than 500,000 patients have received BillionToOne tests to date, and the company has grown from $0M to $150M+ in annual recurring revenue over the past five years.This will be BillionToOne's second year in attendance at the J.P. Morgan Healthcare Conference, and the company will present on the topic of "Redefining Molecular Diagnostics with Single-Molecule Precision." Presentation details are as follows:Location: Mission Bay (32nd Floor) at The WestinDate: Tuesday, January 14, 2025Time: 2:30-2:55 pm PTA webcast and presentation materials will be available on BillionToOne's website: https://billiontoone.com/event/jpm-2025-43rd-annual-healthcare-conference/About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for everyone

BillionToOne
Nov 20th, 2024
BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards

BillionToOne named the Diagnostics Company of the Year by BioTech Breakthrough Awards.

LabPulse
Sep 12th, 2024
BillionToOne to open new facility in Austin, Texas

Molecular diagnostics firm BillionToOne broke ground Wednesday on a 220,000-sq-ft facility in Austin, TX, that is expected to bring 1,000 jobs to the city.

KVUE
Sep 11th, 2024
Molecular diagnostics company bringing 1,000 jobs to Austin

BillionToOne, which is headquartered in California, is set to build a new facility in Austin's EastVillage.

Needles Desert Star
Sep 4th, 2024
BillionToOne Adopting Semaphore Solutions' Labbit LIMS in its Precision Oncology Diagnostics Laboratories

VICTORIA, BC, Sept. 4, 2024 /PRNewswire/ - Semaphore Solutions, a leader in laboratory informatics solutions, is pleased to announce the expansion of its partnership with next-generation molecular diagnostics company, BillionToOne.

Start-Up
Aug 8th, 2024
Zece Unicorni De Anul Acesta Care Ne-Au Atras Atenția

Lectură de 4 minÎn 2013, când a început să fie folosit termenul de ”unicorn” pentru startup-urile tech evaluate la peste 1 miliard de dolari, în lume existau 39 de unicorni. Anul trecut, datele numărau cu puțin peste 1.200 de unicorni, cu o valoare cumulată estimată la 3.856 miliarde de dolari. Anul acesta, în plan global au apărut 38 de unicorni în lumea startup-urilor. Care sunt acele companii care ne-au atras atenția?Înainte de a trece la cei mai noi unicorni ai lumii și la inovația pe care o aduc, reluăm definiția unicornului din punct de vedere al unui startup, așa cum a apărut el în mod original.Un unicorn este un startup de tehnologie privat care a ajuns să fie evaluat la cel puțin un miliard de dolari. Astfel, compania este în fază de dezvoltare și are și particularitate aunui startup, aceea de scalabilitate și a faptului că folosește tehnologia sau aduce un element inovator pentru a avea impact în viețile oamenilor. Ca să se încadreze la ”unicorn”, compania trebuie să fie privată, adică să nu aibă acțiuni la bursă, disponibile publicului larg.În schimb, acțiunile companiei sunt oferite anumitor persoane, ori sunt tranzacționate sau schimbate în mod privat, investitorii fiind cei care setează și bazele evaluării în funcție de sumele pe care aleg să le aloce acelui startup

PR Newswire
Jul 26th, 2024
Billiontoone Announces Green Journal Publication That Underscores The Role Of Cell-Free Dna Nipt For Fetal Red Blood Cell Antigen Genotyping

ACOG supports cfDNA testing as a reasonable alternative for fetal RBC testing among alloimmunized patientsMENLO PARK, Calif., July 26, 2024 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is thrilled to announce a new publication that shows cfDNA analysis is highly sensitive and specific for determining fetal antigen genotype as early as 10 weeks gestation. The new study published online in Obstetrics and Gynecology, the official journal of the American College of Obstetricians and Gynecologists (ACOG), also known as "The Green Journal," supports the implementation of cfDNA testing to manage alloimmunized pregnancies in the United States. This study follows the recent ACOG clinical practice update that supports cfDNA testing as a reasonable alternative to amniocentesis for fetal RBC testing among alloimmunized patients.Hemolytic disease of the fetus or newborn (HDFN) is a potentially life-threatening form of anemia caused by alloimmunization. ACOG recommends testing the reproductive partner's antigen status when alloimmunization is diagnosed in pregnancy. However, rates of reproductive partner screening uptake are low, and results can be misleading in the setting of nonpaternity.In September 2022, BillionToOne's UNITY Fetal Antigen NIPT became the first commercially available cfDNA test in the US, providing highly accurate assessments of the fetal status for RhD, c, C, E, K and Fya antigens. It is the only clinically available NIPT in the US that includes antigens beyond RhD and is offered as an add on to UNITY Complete , the first and only test that uses cell-free DNA to provide precise fetal insights for both recessive and chromosomal conditions.The Green Journal study demonstrates the accuracy of an NGS-based cfDNA analysis assay using BillionToOne's proprietary Quantitative Counting Templates™ (QCT™) for the detection of fetal red blood cell antigen status in a large, diverse U.S.-based cohort

Fierce Biotech
Jun 26th, 2024
DNA testmaker BillionToOne claims billion-dollar valuation with $130M funding round

Diagnostic developer BillionToOne has clocked a billion-dollar valuation, after raising $130 million in venture capital funding. | BillionToOne said the proceeds will help scale up its blood testing businesses in prenatal screening and cancer.

DealStreetAsia
Jun 25th, 2024
India Digest: Dairy brand Sid's Farm bags funding; PremjiInvest leads funding in US-based firm

Sid's Farm has raised $10 million in a Series A round of funding, while PremjiInvest has led a $130-million Series D funding round in US-based BillionToOne.

INACTIVE